# Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

> **NCT06962098** · PHASE2 · RECRUITING · sponsor: **Aptabio Therapeutics, Inc.** · enrollment: 186 (estimated)

## Conditions studied

- Diabetic Kidney Disease (DKD)

## Interventions

- **DRUG:** Isuzinaxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06962098
- **Lead sponsor:** Aptabio Therapeutics, Inc.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962098, "Efficacy and Safety Study of Isuzinaxib in Subjects With DKD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06962098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*